Showing 10,441 - 10,460 results of 19,226 for search '(( significant a decrease ) OR ( significant ((level decrease) OR (mean decrease)) ))', query time: 0.76s Refine Results
  1. 10441

    Image 2_Ticagrelor vs. clopidogrel in dual antiplatelet therapy after coronary artery bypass surgery: a meta-analysis.tif by Liyuan Wang (795570)

    Published 2025
    “…</p>Results<p>4 randomized controlled trials and 3 observational studies (n = 2,424) were eligible for final analysis. A + T was associated with a decreased risk of all-cause mortality (OR = 0.47, 95% CI 0.31–0.70, p < 0.001, p heterogeneity = 0.80, I<sup>2</sup> = 0%) and cardiovascular mortality (OR = 0.50, 95% CI 0.31–0.82, p = 0.006, p heterogeneity = 0.71, I<sup>2</sup> = 0%), compared with A + C group. …”
  2. 10442

    Supplementary file 1_Tracing priming effects in palsa peat carbon dynamics using a stable isotope-assisted metabolomics approach.docx by Christian Ayala-Ortiz (15255371)

    Published 2025
    “…</p>Discussion<p>This suggests that while litter inputs temporarily increase CO<sub>2</sub> emissions, they don’t sustain long-term acceleration of stored carbon decomposition or substantially decrease peat’s carbon store capacity. Our findings demonstrate how technological advancements in analytical tools can provide a more detailed view of carbon cycling processes in complex soil systems.…”
  3. 10443

    Table 1_Mitochondrial oxygen metabolism as a potential predictor of weight loss after laparoscopic sleeve gastrectomy for class III obesity.xlsx by Markus Engelmann (20516393)

    Published 2025
    “…We compared the values obtained in patients with obesity with those of age- and sex-matched healthy controls and investigated changes up to one year after LSG. 48 patients (46.5 years [35.5-55.3]; 38/48 female (79.2%); BMI 46.7 [42.5-51.0]) completed the study. They showed a significant weight loss and a decrease in relative fat mass after six months. …”
  4. 10444

    Table 1_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  5. 10445

    Table1_Age and gender influence on clinical manifestations of thyroid-associated ophthalmopathy: a case series of 2479 Chinese patients.xlsx by Mei Yang (51996)

    Published 2024
    “…Background<p>Significant individual differences exist in the clinical manifestations of thyroid-associated ophthalmopathy (TAO). …”
  6. 10446

    Table 3_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  7. 10447

    Table 2_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  8. 10448

    Inference of cell-type proportions from bulk RNAseq and dynamics during myocardial infarction in α1A-AR-KO mice. by Brian Gural (21781982)

    Published 2025
    “…<b>(E)</b> Results from a Dirichlet regression modeling cell type proportion as influenced by cmAKO, MI, and their interaction, revealing significant effects on several cardiac cell types. …”
  9. 10449

    Table 1_Obstetric and perinatal outcomes in pregnancies conceived with donor versus partner sperm: a systematic review and meta-analysis.docx by Junjie Liu (193511)

    Published 2025
    “…Background<p>Male-related factors contribute to 30-40% of infertility cases, with donor sperm serving as a critical solution for severe male infertility or paternally inherited genetic disorders. …”
  10. 10450

    Image 2_A comprehensive study of hip dislocation: global health burden from 1990 to 2021 and its predictions to 2030.pdf by Xu Zheng (296676)

    Published 2025
    “…</p>Conclusion<p>The disease burden of hip dislocation remains a significant public health challenge. Data-driven analysis is pivotal for guiding clinical practice, shaping public health policies, and ensuring optimal allocation of healthcare resources. …”
  11. 10451

    Image 1_A comprehensive study of hip dislocation: global health burden from 1990 to 2021 and its predictions to 2030.tif by Xu Zheng (296676)

    Published 2025
    “…</p>Conclusion<p>The disease burden of hip dislocation remains a significant public health challenge. Data-driven analysis is pivotal for guiding clinical practice, shaping public health policies, and ensuring optimal allocation of healthcare resources. …”
  12. 10452

    Table 2_A comprehensive study of hip dislocation: global health burden from 1990 to 2021 and its predictions to 2030.docx by Xu Zheng (296676)

    Published 2025
    “…</p>Conclusion<p>The disease burden of hip dislocation remains a significant public health challenge. Data-driven analysis is pivotal for guiding clinical practice, shaping public health policies, and ensuring optimal allocation of healthcare resources. …”
  13. 10453

    Table 1_A comprehensive study of hip dislocation: global health burden from 1990 to 2021 and its predictions to 2030.docx by Xu Zheng (296676)

    Published 2025
    “…</p>Conclusion<p>The disease burden of hip dislocation remains a significant public health challenge. Data-driven analysis is pivotal for guiding clinical practice, shaping public health policies, and ensuring optimal allocation of healthcare resources. …”
  14. 10454

    Data Sheet 1_Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial.pdf by Li-qin Meng (20633030)

    Published 2025
    “…</p>Results<p>Following treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P = 0.013) and a reduction in the frequency of angina episodes (P = 0.021). …”
  15. 10455

    Table 2_The burden of chronic kidney disease attributable to high sodium intake: a longitudinal study in 1990–2019 in China.docx by Yongyao Shen (20561210)

    Published 2025
    “…Despite a slight decreasing trend exists, the absolute number increased as much as twofold, particularly among males and seniors. …”
  16. 10456

    Data_Sheet_1_Safety and efficacy of plasmapheresis in treatment of acute fatty liver of pregnancy—a systematic review and meta-analysis.docx by Sujata Siwatch (19867233)

    Published 2024
    “…Biochemical parameter analysis demonstrated significant improvement post-PP/PE treatment, including decreased bilirubin (MD: 8.30, 95% CI: 6.75 to 9.84), AST (MD: 107.25, 95% CI: 52.45 to 162.06), ALT (MD: 111.08, 95% CI: 27.18 to 194.97), creatinine (MD: 1.66, 95% CI: 1.39 to 1.93), and Prothrombin time (MD: 5.08, 95% CI: 2.93 to 7.22).…”
  17. 10457

    Table 1_The burden of chronic kidney disease attributable to high sodium intake: a longitudinal study in 1990–2019 in China.docx by Yongyao Shen (20561210)

    Published 2025
    “…Despite a slight decreasing trend exists, the absolute number increased as much as twofold, particularly among males and seniors. …”
  18. 10458

    Data_Sheet_2_Safety and efficacy of plasmapheresis in treatment of acute fatty liver of pregnancy—a systematic review and meta-analysis.docx by Sujata Siwatch (19867233)

    Published 2024
    “…Biochemical parameter analysis demonstrated significant improvement post-PP/PE treatment, including decreased bilirubin (MD: 8.30, 95% CI: 6.75 to 9.84), AST (MD: 107.25, 95% CI: 52.45 to 162.06), ALT (MD: 111.08, 95% CI: 27.18 to 194.97), creatinine (MD: 1.66, 95% CI: 1.39 to 1.93), and Prothrombin time (MD: 5.08, 95% CI: 2.93 to 7.22).…”
  19. 10459

    Supplementary file 1_Protective effects and mechanism of resveratrol in animal models of pulmonary fibrosis: a preclinical systematic review and meta-analysis.docx by Yajie Yin (10115902)

    Published 2025
    “…Improved fibrosis: significant reduction in pulmonary fibrosis score (SMD = −2.30, 95% CI [−2.80, −1.79], p < 0.00001, I<sup>2</sup> = 76%) and decreased Hyp content (SMD = −2.16, 95% CI [−2.69, −1.63], p < 0.00001, I<sup>2</sup> = 85%); 2. …”
  20. 10460

    Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... by Yu J. (3610580)

    Published 2024
    “…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”